antivir
drug
current
approv
treat
respiratori
viru
infect
specif
inhibitor
influenza
virus
tabl
howev
consider
progress
made
develop
new
therapeut
respiratori
virus
emerg
new
pathogen
middl
east
respiratori
syndrom
coronaviru
merscov
also
led
screen
effort
identifi
new
therapeut
clinic
studi
examin
novel
target
tabl
combin
design
increas
potenc
reduc
resist
emerg
therapeut
antibodi
immunomodulatori
agent
select
mitig
immunopatholog
host
respons
particularli
influenza
progress
neutral
antibodi
proven
effect
prevent
respiratori
syncyti
viru
rsv
diseas
although
treatment
specif
neutral
antibodi
convalesc
plasma
monoclon
appear
promis
treat
novel
influenza
coronaviru
infect
chapter
review
properti
clinic
applic
current
approv
antivir
agent
amantadin
symmetrel
rimantadin
flumadin
symmetr
tricycl
amin
specif
inhibit
replic
influenza
virus
low
concentr
block
action
circul
strain
influenza
resist
amantadin
rimantadin
four
approv
neuraminidas
inhibitor
laninamivir
oseltamivir
peramivir
zanamivir
neuraminidas
inhibitor
greatest
clinic
impact
start
within
hour
symptom
onset
hospit
adult
children
antiinfluenza
therapi
initi
soon
influenza
consid
delay
confirmatori
test
neuraminidas
inhibitor
appear
reduc
morbid
mortal
among
hospit
adult
children
start
day
possibl
longer
symptom
onset
aerosol
ribavirin
approv
treatment
respiratori
syncyti
viru
rsv
limit
clinic
indic
oral
ribavirin
part
tripl
drug
regimen
influenza
undergo
test
sever
new
antivir
advanc
develop
treatment
respiratori
viral
infect
includ
rsv
rhinoviru
adenoviru
neutral
antibodi
form
convalesc
plasma
monoclon
appear
promis
treatment
novel
influenza
coronaviru
infect
oseltamivir
indic
prophylaxi
children
year
old
treatment
children
week
age
treatment
prophylaxi
dose
recommend
avail
patient
undergo
renal
dialysi
initi
load
dose
mg
age
adjust
equival
maximum
dose
mg
qd
volum
suspens
zanamivir
indic
prophylaxi
children
year
old
treatment
children
year
old
cl
cr
cl
crrt
ratio
creatinin
clearanc
continu
renal
replac
therapi
clearanc
recommend
base
provid
advisori
committe
immun
practic
influenza
b
virus
possess
surfac
glycoprotein
neuraminidas
activ
wherea
influenza
c
virus
figur
enzym
cleav
termin
sialic
acid
residu
variou
glycoconjug
destroy
receptor
recogn
viral
hemagglutinin
activ
essenti
releas
viru
infect
cell
prevent
viral
aggreg
viral
spread
within
respiratori
tract
oseltamivir
prodrug
activ
carboxyl
laninamivir
peramivir
pharmacokinet
properti
antivir
activ
influenza
decreas
bioavail
prodrug
parent
elimin
primarili
unchang
kidney
glomerular
filtrat
anion
tubular
secret
dose
reduc
half
patient
creatinin
clearanc
less
mlmin
reduct
clearanc
mlmin
distribut
well
character
human
peak
bronchoalveolar
lavag
middl
ear
fluid
sinu
fluid
level
similar
plasma
level
recent
data
suggest
signific
relationship
exist
oseltamivir
carboxyl
auc
area
curv
auc
symptom
score
time
allevi
composit
symptom
score
time
cessat
viral
shed
experiment
infect
volunt
oseltamivir
avail
oral
deliveri
oseltamivir
come
mg
tablet
white
tuttifruttiflavor
suspens
mg
oseltamivir
base
final
concentr
mgml
approv
adult
dose
treatment
mg
twice
daili
day
prophylaxi
mg
daili
pediatr
dose
base
weight
outlin
oseltamivir
indic
prevent
influenza
infect
patient
year
dose
day
efficaci
oncedaili
oseltamivir
mg
week
prevent
influenza
ill
healthi
nonimmun
adult
prevent
influenza
infect
irrespect
symptom
immun
nurs
home
resid
efficaci
prophylaxi
ill
compar
placebo
somewhat
lower
efficaci
seen
householdcontact
prophylaxi
studi
protect
influenza
shown
children
season
prophylaxi
highrisk
immunocompromis
patient
document
provid
protect
efficaci
rtpcrconfirm
influenza
ill
caution
use
prescrib
oseltamivir
prophylaxi
patient
expos
index
case
prophylaxi
associ
emerg
resist
mutant
empir
therapi
monitor
gener
recommend
case
result
postexposur
prophylaxi
nurs
home
influenza
outbreak
advis
day
least
day
last
cultureconfirm
ill
ward
build
effect
regimen
given
concomit
influenza
vaccin
previous
provid
season
prophylaxi
week
peak
influenza
viru
circul
within
commun
use
protect
highrisk
patient
toler
immun
develop
adequ
immun
respons
vaccin
strain
circul
commun
match
vaccin
strain
oseltamivir
mg
twice
daili
day
start
within
first
day
symptom
associ
shorter
time
allevi
uncompl
influenza
ill
hour
shorter
reduct
sever
ill
durat
fever
time
return
normal
activ
quantiti
viral
shed
durat
impair
activ
complic
lead
antibiot
use
particularli
bronchiti
compar
placebo
previous
healthi
adult
one
recent
studi
bangladesh
suggest
oseltamivir
may
efficaci
hour
symptom
onset
children
pediatr
studi
enrol
children
young
week
age
demonstr
oseltamivir
safe
associ
significantli
reduc
ill
durat
sever
time
resumpt
full
activ
occurr
complic
lead
antibiot
use
particularli
acut
otiti
media
exist
literatur
safeti
efficaci
oseltamivir
elderli
highrisk
person
includ
underli
cardiopulmonari
condit
immunodefici
come
observ
studi
suggest
among
high
risk
hospit
individu
benefit
start
antivir
therapi
least
day
symptom
onset
greatest
benefit
patient
start
within
hour
symptom
onset
zanamivir
sialic
acid
analog
potent
specif
inhibit
influenza
b
neuraminidas
competit
revers
interact
activ
enzym
site
drug
activ
nine
influenza
neuraminidas
subtyp
natur
oseltamivir
zanamivir
global
avail
laninamivir
approv
japan
peramivir
approv
china
japan
south
korea
usa
laninamivir
octano
prodrug
convert
airway
laninamivir
activ
neuraminidas
inhibitor
retain
concentr
exceed
ic
influenza
neuraminidas
least
hour
day
singl
inhal
mg
drug
system
absorb
inhal
laninamivir
excel
vitro
activ
wildtyp
influenza
b
virus
current
circul
includ
virus
contain
mutat
neuraminidas
laninamivir
octano
current
approv
japan
avail
mg
dri
powder
inhal
undergo
clinic
investig
outsid
japan
present
laninamivir
approv
prevent
influenza
adult
children
year
age
singl
inhal
mg
daili
day
recommend
indic
among
household
contact
index
patient
influenza
day
laninamivir
mg
daili
associ
protect
efficaci
respect
compar
placebo
laninamivir
approv
treatment
prevent
influenza
b
infect
japan
treatment
laninamivir
approv
singl
inhal
mg
individu
year
age
mg
children
less
year
age
laninamivir
associ
rapid
time
allevi
influenza
ill
due
infect
season
viru
substitut
children
compar
standard
oseltamivir
regimen
studi
adult
demonstr
noninferior
versu
oseltamivir
patient
laninamivir
demonstr
similar
durat
fever
ambulatori
children
compar
patient
treat
zanamivir
dose
adjust
current
indic
patient
popul
clinic
studi
asia
found
similar
rate
nausea
laninamivir
octanoateand
oseltamivirtr
patient
lower
rate
vomit
laninamivir
octano
arm
similar
slightli
higher
rate
diarrhea
laninamivir
octano
arm
dizzi
seen
laninamivir
octanoatetr
patient
oseltamivirtr
patient
laninamivir
associ
signific
bronchospasm
respiratori
advers
effect
patient
chronic
respiratori
diseas
oseltamivir
oral
oseltamivir
ethyl
ester
well
absorb
rapidli
cleav
esteras
gastrointestin
tract
liver
blood
bioavail
activ
metabolit
oseltamivir
carboxyl
estim
previous
healthi
person
see
tabl
plasma
elimin
halflif
hour
prolong
elderli
although
dose
adjust
gener
necessari
administr
food
appear
decreas
risk
gastrointestin
upset
without
studi
hospit
adult
suggest
earli
therapi
associ
reduc
incid
lower
respiratori
tract
complic
requir
iculevel
care
durat
ill
durat
shed
mortal
usual
oseltamivir
dose
reduc
mg
day
treatment
mg
everi
day
mg
suspens
daili
prophylaxi
patient
creatinin
clearanc
mlmin
dose
oseltamivir
given
hemodialysi
detail
dose
renal
insuffici
renal
replac
therapi
avail
tabl
safeti
pharmacokinet
patient
hepat
impair
evalu
sever
studi
pregnanc
suggest
oseltamivir
like
safe
provid
clear
therapeut
benefit
pregnant
women
infect
influenza
conflict
data
optim
dose
oseltamivir
pregnant
women
studi
suggest
need
higher
dose
mg
tid
other
suggest
dose
adjust
need
current
guidelin
recommend
treat
pregnant
women
influenza
infect
one
approv
neuraminidas
inhibitor
recommend
pediatr
dosag
list
tabl
doubl
treatment
dose
oseltamivir
hospit
influenza
patient
appear
increas
virolog
efficaci
except
perhap
influenza
b
infect
clinic
effect
although
one
icubas
rct
report
tripl
standard
dose
associ
acceler
viral
rna
clearanc
respiratori
tract
oral
oseltamivir
gener
well
toler
seriou
endorgan
toxic
found
control
clinic
trial
oseltamivir
associ
nausea
abdomin
discomfort
less
often
emesi
minor
treat
patient
nausea
vomit
occur
approxim
excess
frequenc
oseltamivir
recipi
gastrointestin
complaint
typic
mildtomoder
intens
usual
resolv
despit
continu
dose
amelior
administr
food
clinic
studi
compar
mg
mg
twice
daili
found
similar
frequenc
advers
event
two
dose
infrequ
possibl
advers
event
includ
insomnia
vertigo
fever
postmarket
report
suggest
oseltamivir
may
associ
rare
skin
rash
hepat
dysfunct
thrombocytopenia
addit
report
abnorm
neurolog
behavior
symptom
rare
result
death
among
mostli
children
report
come
japan
exist
data
suggest
event
like
secondari
influenza
infect
oseltamivir
therapi
current
recommend
patient
monitor
close
behavior
abnorm
clinic
signific
drug
interact
recogn
date
includ
studi
amoxicillin
aspirin
acetaminophen
interact
cytochrom
enzym
occur
vitro
oseltamivir
affect
steadyst
pharmacokinet
commonli
use
immunosuppress
agent
howev
probenecid
block
tubular
secret
doubl
halflif
oseltamivir
protein
bind
oseltamivir
affect
immunogen
concomit
inactiv
viru
vaccin
might
impair
immunogen
concurr
liveattenu
intranas
influenza
vaccin
peramivir
low
oral
bioavail
therefor
deliv
intraven
peramivir
achiev
except
high
maximum
concentr
ngml
mg
intraven
dose
excel
concentr
drug
nasal
pharyng
secrect
peramivir
predomin
elimin
unchang
renal
excret
plasma
termin
elimin
halflif
hour
peramivir
compar
lower
activ
vitro
influenza
b
virus
oseltamivir
carboxyl
zanamivir
peramivir
avail
mg
mg
solut
intraven
use
peramivir
random
clinic
trial
conduct
previous
healthi
adult
children
infect
uncompl
influenza
compar
placebo
singl
mg
infus
peramivir
associ
significantli
shorter
time
allevi
symptom
significantli
shorter
time
resumpt
usual
activ
rapid
clearanc
viru
anoth
studi
found
singl
mg
infus
peramivir
noninferior
day
oral
oseltamivir
mg
bid
season
mani
virus
resist
oseltamivir
result
mutat
data
question
efficaci
peramivir
manag
virus
mutat
studi
compar
day
mg
mg
qd
peramivir
oral
oseltamivir
mg
bid
hospit
adult
trend
toward
rapid
resumpt
usual
activ
peramivirtr
patient
greater
reduct
influenza
b
viral
titer
nasopharynx
oseltamivir
first
h
sinc
peramivir
renal
clear
dose
must
adjust
base
renal
function
see
tabl
limit
data
guid
dose
peramivir
children
particularli
among
neonat
avail
data
model
suggest
patient
receiv
intermitt
hemodialysi
need
dose
adjust
see
tabl
dose
patient
continu
renal
replac
therapi
crrt
base
crrt
clearanc
limit
dose
inform
patient
extracorpor
membran
oxygen
ecmo
base
model
data
predict
drug
concentr
recommend
children
day
year
receiv
mgkg
daili
daili
maximum
mgdose
infant
day
receiv
mgkg
daili
infant
day
receiv
mgkg
daili
neonat
day
receiv
mgkg
daili
dose
adjust
need
hepat
impair
recogn
advers
event
associ
administr
peramivir
diarrhea
nausea
vomit
neutrophil
count
decreas
less
common
advers
event
observ
studi
date
includ
dizzi
headach
somnol
nervous
insomnia
feel
agit
depress
nightmar
hyperglycemia
hyperbilirubinemia
elev
blood
pressur
cystiti
ecg
abnorm
anorexia
proteinuria
oral
bioavail
zanamivir
low
clinic
trial
use
intranas
dri
powder
inhal
deliveri
follow
inhal
dri
powder
approxim
deposit
lower
respiratori
tract
remaind
oropharynx
median
zanamivir
concentr
ngml
induc
sputum
hour
inhal
remain
detect
hour
later
peak
plasma
concentr
averag
singl
mg
inhal
zanamivir
proprietari
inhal
devic
deliv
zanamivir
breathactu
requir
cooper
patient
intraven
zanamivir
display
linear
dose
kinet
volum
distribut
approxim
equival
extracellular
water
intraven
zanamivir
provid
high
peak
plasma
concentr
ngml
mg
dose
adult
drug
excret
unchang
urin
elimin
halflif
approxim
hour
intraven
zanamivir
clearanc
highli
correl
renal
function
cl
clcr
zanamivir
deliv
inhal
proprietari
breathactiv
devic
usual
adult
treatment
dose
two
inhal
mg
twice
day
day
intraven
zanamivir
current
advanc
clinic
develop
avail
compassion
use
zanamivir
indic
oncedaili
inhal
prevent
influenza
patient
year
old
oncedaili
inhal
zanamivir
week
efficaci
prevent
laboratoryconfirm
ill
fever
effect
prevent
influenza
infect
irrespect
symptom
use
postexposur
prophylaxi
inhal
zanamivir
day
reduc
risk
secondari
influenza
ill
household
nurs
home
experienc
influenza
outbreak
inhal
zanamivir
effect
prevent
influenza
ill
oral
rimantadin
part
frequent
resist
emerg
inhibitor
usa
zanamivir
indic
treatment
uncompl
acut
ill
due
influenza
b
virus
adult
pediatr
patient
year
older
symptomat
day
inhal
zanamivir
adult
consist
shown
least
fewer
day
disabl
influenza
symptom
studi
found
reduct
number
night
disturb
sleep
time
resumpt
normal
activ
use
symptom
relief
medic
similar
therapeut
benefit
also
shown
children
age
year
old
zanamivir
also
associ
reduct
lower
respiratori
tract
complic
influenza
lead
antibiot
particularli
bronchiti
pneumonia
zanamivir
appear
gener
well
toler
effect
treat
influenza
patient
mildtomoder
asthma
less
often
chronic
obstruct
pulmonari
diseas
intraven
zanamivir
advanc
clinic
develop
use
serious
ill
influenza
patient
especi
suspect
oseltamivirresist
variant
emerg
ind
eind
use
intraven
zanamivir
patient
clinic
fail
antivir
therapi
least
patient
proven
clinic
suspect
resist
oseltamivir
avail
data
patient
treat
eind
demonstr
among
report
outcom
die
despit
therapi
phase
studi
critic
ill
pandem
patient
found
treatment
associ
signific
antivir
effect
even
though
therapi
initi
median
day
symptom
onset
patient
influenza
detect
initi
sampl
day
therapi
associ
median
log
copiesml
declin
viral
load
drugrel
trend
safeti
paramet
identifi
allcaus
mortal
rate
respect
phase
studi
compar
iv
zanamivir
oral
oseltamivir
hospit
adult
current
progress
although
plasma
elimin
halflif
increas
creatinin
clearanc
mlmin
drug
accumul
neglig
inhal
dose
adjust
necessari
renal
hepat
dysfunct
certain
popul
particularli
young
frail
cognit
impair
patient
may
difficulti
use
drug
deliveri
system
intraven
zanamivir
requir
dose
adjust
renal
insuffici
patient
receiv
initi
mg
load
dose
mainten
dose
dose
interv
reduc
worsen
renal
function
see
tabl
topic
appli
zanamivir
gener
well
toler
control
studi
includ
involv
patient
asthma
chronic
obstruct
pulmonari
diseas
postmarket
report
indic
bronchospasm
may
uncommon
potenti
sever
problem
particularli
patient
acut
influenza
underli
reactiv
airway
diseas
anecdot
report
hospit
fatal
indic
inhal
zanamivir
use
cautious
patient
low
bioavail
associ
low
exposur
circul
zanamivir
clinic
signific
drug
interact
recogn
vitro
studi
suggest
zanamivir
inhibit
induc
cytochrom
enzym
drug
affect
immunogen
concomit
immun
inactiv
viru
vaccin
effect
intranas
liveattenu
vaccin
studi
one
random
control
trial
ambulatori
adult
found
combin
inhal
zanamivir
oral
oseltamivir
less
effect
oseltamivir
monotherapi
zanamivir
associ
teratogen
effect
preclin
studi
fda
pregnanc
categori
c
consid
option
pregnant
women
proven
influenza
neuraminidas
inhibitor
resist
vitro
result
mutat
viral
hemagglutinin
andor
neuraminidas
hemagglutinin
variant
mutat
near
receptor
bind
site
make
viru
less
depend
neuraminidas
action
wherea
neuraminidas
mutat
directli
affect
interact
inhibitor
alter
neuraminidas
typic
show
reduc
activ
stabil
mutat
virus
usual
decreas
infect
anim
particular
neuraminidas
mutat
determin
degre
resist
crossresist
ie
caus
highlevel
resist
oseltamivir
zanamivir
result
reduc
suscept
oseltamivir
zanamivir
oseltamivirresist
variant
recov
treat
adult
treat
children
assess
resist
assess
sequenc
ha
na
gene
phenotyp
test
ribavirin
ribavirin
guanosin
analog
wide
rang
antivir
activ
includ
influenza
virus
rsv
parainfluenza
virus
ribavirin
rapidli
phosphoryl
intracellular
enzym
triphosph
inhibit
influenza
viru
rna
polymeras
activ
competit
inhibit
guanosin
triphosphatedepend
influenza
viral
messeng
rna
addit
ribavirin
deplet
cellular
guanin
pool
may
inhibit
viru
replic
lethal
mutagenesi
oral
ribavirin
bioavail
adult
children
achiev
peak
plasma
concentr
hour
ingest
mg
dose
adult
ribavirin
short
initi
hour
long
termin
hour
phase
halflif
elimin
hepat
metabol
renal
clearanc
aerosol
administr
plasma
level
increas
exposur
rang
respiratori
secret
level
ml
declin
halflif
hour
ribavirin
come
three
formul
oral
approv
combin
use
hepat
c
intraven
investig
usa
aerosol
ribavirin
aerosol
avail
ml
solut
dilut
final
concentr
mgml
deliv
small
particl
aerosol
hour
proprietari
devic
nebul
higher
concentr
aerosol
solut
mgml
given
hour
three
time
daili
studi
appear
improv
mortal
reduc
durat
viral
replic
rel
treatment
system
ribavirin
contraind
patient
creatinin
clearanc
mlmin
dose
reduc
onethird
patient
year
age
dose
adjust
need
substanti
declin
hematocrit
drug
discontinu
hemoglobin
drop
gdl
fix
combin
oseltamivir
amantadin
ribavirin
activ
vitro
suscept
resist
strain
show
promis
clinic
manag
influenza
infect
system
ribavirin
caus
doserel
extravascular
hemolyt
anemia
higher
dose
suppress
bone
marrow
releas
erythroid
element
aerosol
ribavirin
caus
bronchospasm
mild
conjunctiv
irrit
rash
psycholog
distress
administ
oxygen
tent
rare
acut
water
intox
bolu
intraven
administr
may
caus
rigor
antagon
drug
may
occur
ribavirin
combin
zidovudin
ribavirin
contraind
pregnant
women
male
partner
women
pregnant
teratogen
drug
pregnanc
avoid
therapi
month
complet
therapi
femal
patient
femal
partner
male
patient
take
ribavirin
pregnanc
categori
x
refer
avail
onlin
expertconsultcom
well
toler
ribavirin
also
come
mg
tablet
steril
solut
inject
ribavirin
aerosol
current
indic
treatment
sever
rsv
children
trial
aerosol
ribavirin
treatment
sever
rsv
infect
infant
shown
consist
effect
durat
hospit
time
mortal
pulmonari
function
current
guidelin
recommend
aerosol
ribavirin
consid
treatment
highrisk
infant
young
children
defin
congenit
heart
diseas
chronic
lung
diseas
immunodefici
state
prematur
age
week
well
hospit
sever
ill
aerosol
ribavirin
shown
minim
efficaci
treat
influenza
hospit
children
ribavirin
also
studi
treatment
rsv
parainfluenza
viru
infect
immunocompromis
patient
intraven
ribavirin
appear
ineffect
reduc
rsvassoci
mortal
hematopoiet
stem
cell
transplant
hsct
patient
rsv
pneumonia
may
benefit
among
lung
transplant
recipi
aerosol
ribavirin
may
provid
benefit
select
patient
group
less
sever
rsv
diseas
surviv
improv
treatment
start
respiratori
failur
infect
limit
upper
respiratori
tract
observ
studi
suggest
combin
therapi
antibodi
either
intraven
immunoglobulin
respigam
palivizumab
appear
effect
particularli
start
sever
respiratori
distress
oral
ribavirin
tri
manag
rsv
variabl
success
manag
parainfluenza
viru
bone
marrow
transplant
recipi
two
case
seri
found
aerosol
ribavirin
fail
